{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glomerulopathy&page=2",
    "query": {
      "condition": "Glomerulopathy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glomerulopathy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T03:29:40.508Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03301467",
      "title": "Controlled Trial Evaluating Avacopan in C3 Glomerulopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "C3 Glomerulopathy (C3G)"
      ],
      "interventions": [
        {
          "name": "Avacopan",
          "type": "DRUG"
        },
        {
          "name": "Avacopan Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2017-09-29",
      "completion_date": "2021-10-27",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 10,
      "location_summary": "Palo Alto, California • Chicago, Illinois • Iowa City, Iowa + 7 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03301467"
    },
    {
      "nct_id": "NCT07498335",
      "title": "Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Berger Disease",
        "Bergers Disease",
        "IgA Nephropathy",
        "Immunoglobulin A Nephropathy",
        "Primary IgAN",
        "Nephritis IgA Type, Nephropathy IgA Type"
      ],
      "interventions": [
        {
          "name": "Drug: Atrasentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 28,
      "start_date": "2026-08-26",
      "completion_date": "2032-12-13",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 4,
      "location_summary": "Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07498335"
    },
    {
      "nct_id": "NCT00446459",
      "title": "Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Failure, Chronic",
        "Diabetic Nephropathies",
        "Glomerulonephritis, IGA",
        "Hypertension, Renal"
      ],
      "interventions": [
        {
          "name": "mycophenolate mofetil (CellCept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2006-04",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2010-04-15",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00446459"
    },
    {
      "nct_id": "NCT05809531",
      "title": "An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "C3G",
        "IC-MPGN",
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Complement 3 Glomerulopathy",
        "Complement 3 Glomerulopathy (C3G)",
        "Complement 3 Glomerulonephritis",
        "Dense Deposit Disease",
        "DDD",
        "Membranoproliferative Glomerulonephritis",
        "Membranoproliferative Glomerulonephritis (MPGN)",
        "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2023-05-29",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Gainsville, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05809531"
    },
    {
      "nct_id": "NCT00977977",
      "title": "Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nephrotic Syndrome",
        "Proteinuria",
        "Autoimmune Disease",
        "Glomerular Disease",
        "Membranous Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "Rituximab Infusion",
          "type": "DRUG"
        },
        {
          "name": "Oral Cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-12-22",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00977977"
    },
    {
      "nct_id": "NCT04939116",
      "title": "Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerular Disease",
        "Proteinuria"
      ],
      "interventions": [
        {
          "name": "ANG-3070",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Angion Biomedica Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-12-24",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2022-03-23",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Northridge, California • Vacaville, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Vacaville",
          "state": "California"
        },
        {
          "city": "Lauderdale Lakes",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04939116"
    },
    {
      "nct_id": "NCT04080076",
      "title": "Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Disease"
      ],
      "interventions": [
        {
          "name": "Acthar 80 UNT/ML Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Oral Tab Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NephroNet, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "65 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2019-01-12",
      "completion_date": "2024-09-06",
      "has_results": false,
      "last_update_posted_date": "2022-09-22",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 1,
      "location_summary": "Lawrenceville, Georgia",
      "locations": [
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04080076"
    },
    {
      "nct_id": "NCT02682407",
      "title": "Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgAN",
        "LN",
        "MN",
        "C3G"
      ],
      "interventions": [
        {
          "name": "OMS721 (narsoplimab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Omeros Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2016-03-10",
      "completion_date": "2020-08-25",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Evergreen Park",
          "state": "Illinois"
        },
        {
          "city": "Voorhees Township",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02682407"
    },
    {
      "nct_id": "NCT07268638",
      "title": "A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Praliciguat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-12-03",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 23,
      "location_summary": "Chula Vista, California • Los Angeles, California • San Dimas, California + 19 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        },
        {
          "city": "Arvada",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07268638"
    },
    {
      "nct_id": "NCT05003986",
      "title": "Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis",
        "Minimal Change Disease",
        "Immunoglobulin A Nephropathy",
        "IgA Vasculitis",
        "Alport Syndrome"
      ],
      "interventions": [
        {
          "name": "Sparsentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Travere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 67,
      "start_date": "2021-08-12",
      "completion_date": "2027-04-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-07-23T03:29:40.508Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05003986"
    }
  ]
}